Medigene AG to present at the 8th CAR-TCR Summit in Boston
Planegg/Martinsried (22.08.2023) Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 8th CAR-TCR Summit in Boston from August 29 to September 1, 2023.
On August 30, 2023, Medigene's CSO Prof. Schendel will present on the topic "Improving TCR-T Therapeutic Persistence Efficacy with Switch Receptors" (see details below).
CAR-TCR Summit 2023
Date: August 30, 2023, 5:00 pm local time
Presenter: Prof. Dr. Dolores Schendel, CSO
Presentation: Improving TCR-T Therapeutics Persistence Efficacy with Switch Receptors
--- end of press release ---
About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell therapies to effectively eliminate cancer. Its end-to-end technology platform, built on multiple proprietary and exclusive product development and product enhancement technologies, allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact details
Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: [email protected]
LifeSci Advisors
Sandya von der Weid
Phone: +41 78 680 05 38
E-mail: [email protected]
Emitter: |
Medigene AG Lochhamer Straße 11 82152 Planegg/Martinsried Germany |
Contact Person: |
Medigene PR/IR |
Phone: |
+49 89 2000 3333 01 |
E-Mail: |
|
Website: |
|
ISIN(s): |
DE000A1X3W00 (Share) |
Stock Exchange(s): |
Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate |
Medigene AG Stock
With 1 Buy predictions and 2 Sell predictions the community is currently undecided on Medigene AG.
With a target price of 1 € there is a slightly negative potential of -16.67% for Medigene AG compared to the current price of 1.2 €.
